{"url_path":"/sec/eldn/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","accession_number":"0001193125-26-221702","cik":"0001404281","ticker":"ELDN","issuer_name":"Eledon Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","primary_entity_key":"0001404281","primary_entity_name":"Eledon Pharmaceuticals, Inc."},"word_count":72,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.\n\nOn January 13, 2026, the Company completed the issuance of 395,964 shares of its common stock, $0.001 par value per share, to a life sciences-focused lending partner in settlement of a cancellation fee payable to the third party in the amount of $591,393. The shares were sold pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act."}